Anemia correction by erythropoietin reduces BNP levels, hospitalization rate, and NYHA class in patients with cardio-renal anemia syndrome.
Little is known about the effect of anemia correction with erythropoietin (EPO) on B-type natriuretic peptide (BNP) levels, NYHA class, and hospitalization rate. The aim of the study was to investigate, in patients with cardio-renal anemia syndrome, the effects of EPO on hemochrome and renal function parameters and BNP levels. We also analyzed the effect of EPO therapy on hospitalization rate and NYHA class after 12 months in comparison with a population undergoing to standard therapy. We performed a randomized double-blind controlled study of correction of the anemia with subcutaneous α (group A n = 13) or β (group B n = 14) EPO for 12 months in addition to standard therapy with oral iron in 27 subjects. Control group (n = 25 patients) received only oral iron. Significant increase in hemoglobin (Hb), hematocrit (Hct), and red blood cells (RBC) were revealed in EPO groups at 12 months; Hb, group A 12.3 ± 0.6; group B 11.7 ± 0.8; control group 10.6 ± 0.5 g/dl P < 0.0001; Hct group A 34.2 ± 2.3, group B 34 ± 2, control group 32.3 ± 1.8% P < 0.01; RBC, group A 3.9 ± 0.2, group B 3.8 ± 0.2, control group 3.3 ± 0.2, (P < 0.0001). Plasma BNP levels in EPO groups were significantly reduced after 12 months (group A: 335 ± 138 vs. group B: 449 ± 274 pg/ml control group 582 ± 209 pg/ml (P < 0.01). After 12 months of treatment, hospitalization rate and NYHA class were reduced in EPO groups with respect to control group (P < 0.05). Finally, an inverse correlation was observed between BNP and Hb levels in EPO Groups (r = -0.70 P < 0.001). EPO treatment reduces BNP levels and hospitalization rate in patients with cardio-renal anemia syndrome. The correction of anemia by EPO treatment appears able to improve clinical outcome in this subset of patients with heart failure.
Palazzuoli
Alberto
A
Cardiology Section, Department of Internal Medicine and Metabolic Diseases, Le Scotte Hospital, University of Siena, Viale Bracci, 53100 Siena, Italy. palazzuoli2@unisi.it
Quatrini
Ilaria
I
Calabrò
Anna
A
Antonelli
Giovanni
G
Caputo
Maria
M
Campagna
Maria S
MS
Franci
Beatrice
B
Nuti
Ranuccio
R
D000284:Administration, Oral; D000740:Anemia / Q000188:drug therapy*; D004921:Erythropoietin / Q000008:administration & dosage*; D006333:Heart Failure / Q000150:complications*; D006454:Hemoglobins / Q000032:analysis; D006760:Hospitalization / Q000706:statistics & numerical data*; D006801:Humans; D007279:Injections, Subcutaneous; D007501:Iron / Q000008:administration & dosage; D007674:Kidney Diseases / Q000150:complications*; D020097:Natriuretic Peptide, Brain / Q000097:blood*; D012720:Severity of Illness Index; D016896:Treatment Outcome
C554270:EPO protein, human; D006454:Hemoglobins; D004921:Erythropoietin; D020097:Natriuretic Peptide, Brain; D007501:Iron